Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Prostatic Neoplasms 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

pertuzumab 3Vorinostat 3Specimen Handling 3Azacitidine 3venetoclax 2trametinib 2ruxolitinib 2pembrolizumab 2palbociclib 2dabrafenib 2copanlisib 2aflibercept 2abiraterone 2Trastuzumab 2Sunitinib 2Sorafenib 2Oxaliplatin 2Nivolumab 2Magnetic Resonance Spectroscopy 2Leucovorin 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Doxorubicin 2Disulfides 2Dasatinib 2Biopsy 2Bevacizumab 2Afatinib 2Ado-Trastuzumab Emtansine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Inosine Monophosphate × Other hematologic neoplasm × Clear all
NCT07474051 2026-03-16

PERSIST

AvenCell Therapeutics, Inc.

Enrolling by invitation
178 enrolled
GenitourinaryLymphoidOther hematologic neoplasm

Prostatic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡